ImmunoPrecise Antibodies Ltd. (NASDAQ:HYFT) — Market Cap & Net Worth
Market Cap & Net Worth: ImmunoPrecise Antibodies Ltd. (HYFT)
ImmunoPrecise Antibodies Ltd. (NASDAQ:HYFT) has a market capitalization of $61.17 Million ($61.17 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21225 globally and #4781 in its home market, demonstrating a 1.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ImmunoPrecise Antibodies Ltd.'s stock price $1.31 by its total outstanding shares 46691281 (46.69 Million). Also see ImmunoPrecise Antibodies Ltd. (HYFT) total assets for a full breakdown of the balance sheet.
ImmunoPrecise Antibodies Ltd. Market Cap History: 2025 to 2026
ImmunoPrecise Antibodies Ltd.'s market capitalization history from 2025 to 2026. Data shows growth from $84.98 Million to $61.17 Million (0.00% CAGR). Also see HYFT operating cash flow for how efficiently the company converts equity into cash flow.
ImmunoPrecise Antibodies Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ImmunoPrecise Antibodies Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ImmunoPrecise Antibodies Ltd. share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.50x
ImmunoPrecise Antibodies Ltd.'s market cap is 3.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $84.98 Million | $24.31 Million | -$29.97 Million | 3.50x | N/A |
Competitor Companies of HYFT by Market Capitalization
Companies near ImmunoPrecise Antibodies Ltd. in the global market cap rankings as of September 18, 2026. Review ImmunoPrecise Antibodies Ltd. tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ImmunoPrecise Antibodies Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
ImmunoPrecise Antibodies Ltd. Historical Marketcap From 2025 to 2026
Between 2025 and today, ImmunoPrecise Antibodies Ltd.'s market cap moved from $84.98 Million to $ 61.17 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $61.17 Million | -28.02% |
| 2025 | $84.98 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of ImmunoPrecise Antibodies Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $61.17 Million USD |
| MoneyControl | $61.17 Million USD |
| MarketWatch | $61.17 Million USD |
| marketcap.company | $61.17 Million USD |
| Reuters | $61.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more